Divine Aleru, Microbiome Signatures Research Coordinator

This study shows that Escherichia coli Nissle exerts strong dose dependent amebicidal activity against Entamoeba histolytica through oxidative stress and structural damage, highlighting its therapeutic potential.

Escherichia coli Nissle 1917 inhibited Candida albicans growth, reduced virulence traits and protected intestinal cells, showing strong preventive potential through contact based and soluble antifungal mechanisms.

This study shows that Klebsiella pneumoniae L fucose metabolism enhances gut colonization, strengthens biofilm and adherence traits, and increases virulence signalling, identifying a functional metabolic signature relevant to microbiome based clinical risk.

This study shows that the immuno modulatory effect of Escherichia coli Nissle 1917 primes polarized colonic cells, reduces Campylobacter jejuni adhesion and survival, and rebalances NF kappa B, MAPK and Akt signaling to limit inflammation and epithelial injury.

This study shows how Escherichia coli Nissle 1917 inhibitory mechanisms act through adhesion and suppression of EPEC virulence, defining a strong microbiome signature of pathogen interference.

This study shows that Escherichia coli Nissle 1917 microcin MccM is the key factor driving EcN’s inhibition of Salmonella, improving pathogen suppression, reducing cell invasion, and lowering inflammatory cytokine responses.

This study shows that DegP secretion drives probiotic Escherichia coli DegP biofilm inhibition by repressing pathogenic biofilms through a targeted extracellular mechanism that shapes microbial competition.

This study shows how F1C fimbriae in Escherichia coli Nissle 1917 drive biofilm formation, epithelial adhesion, and intestinal persistence, defining a functional microbiome signature for stable colonization.

This review explains how adhesive threads of extraintestinal pathogenic Escherichia coli shape gut colonization, tissue tropism and invasive disease and shows how detailed adhesin profiles can inform microbiome based risk assessment and vaccine design.

This review explores how gut microbiota modulation influences ovarian aging and presents potential therapies like fecal microbiota transplantation and probiotics to prevent or alleviate ovarian aging, offering new strategies for preserving reproductive health.

This review explores the complex role of microbial metabolites in cancer, focusing on their impact on tumor initiation, progression, metastasis, and therapy response. It highlights how microbial products influence the tumor microenvironment and immune modulation, suggesting new avenues for cancer therapy.

This review explores the role of microbiome-derived metabolites in inflammation-related cancer prevention and treatment, highlighting their dual effects in modulating inflammation and immune responses. It discusses key metabolites such as SCFAs, polyamines, and bile acids, along with emerging therapies and the challenges in translating these findings into clinical practice.

This review explores the dual role of gut microbial metabolites in cancer, focusing on their anticancer and pro-carcinogenic effects. It emphasizes the potential of SCFAs, bacteriocins, and dietary modifications in preventing and treating cancer, with a focus on colorectal cancer and other common malignancies.

E. coli Nissle 1917 demonstrates significant antibiofilm activity against P. aeruginosa, inhibiting biofilm formation and dispersing mature biofilms. Its CFS also downregulates key virulence factors and offers protection in a Galleria mellonella model.

This review shows how Salmonella reshapes the gut environment and engages in Salmonella gut infection antagonistic interbacterial interactions with commensals, and it explains how bacteriocins and type six secretion systems shape microbiome signatures and infection risk.

his review shows how siderophore microcins in Escherichia coli support competitive gut colonization, connect the fecal reservoir with urinary tract infection, and define functional microbiome signatures that combine B2 background with microcin, salmochelin and colibactin islands.

This review explains intestinal effect of Escherichia coli Nissle 1917 and its vesicles on the gut barrier, dysbiosis and mucosal immunity, and it links these microbial actions to clinical outcomes in inflammatory bowel disease and acute diarrhoea.

Oral delivery of a glypican-1–flagellin fusion by engineered EcN triggered systemic IgG and regulatory IL-10 in mice, confirming a safe probiotic cancer-vaccine chassis but indicating the need for stronger cellular adjuvanticity for PDAC.

Engineered Escherichia coli Nissle 1917 Pseudomonas aeruginosa control was tested as a live targeted therapy for gut infection. The authors rebuilt the earlier “sense-and-kill” circuit in a clinically used EcN background. The circuit sensed the P. aeruginosa quorum signal 3OC12-HSL. It then triggered lysis and release of pyocin S5, an antipseudomonal bacteriocin. […]

Engineered EcN for phenylketonuria was upgraded to SYNB1934 using biosensor-enabled PAL evolution, doubling gut phenylalanine conversion and keeping biocontainment, supporting development of an oral strain for diet-refractory PKU.

Engineered Escherichia coli Nissle 1917 for hyperammonemia (SYNB1020) safely consumed gut ammonia, improved survival in mice, and showed dose-linked metabolic activity and clearance in healthy adults, supporting clinical development for urea cycle and liver-related hyperammonemia.

Engineering Escherichia coli Nissle 1917 therapeutics enables targeted antimicrobial, mucosal, metabolic, and anticancer actions but requires parallel engineering for biosafety and colibactin control.

Escherichia coli Nissle 1917, a probiotic strain, offers significant health benefits, but its genotoxic potential due to colibactin production raises safety concerns, particularly in relation to colorectal cancer. The review underscores the need for further research on the balance between benefits and risks.

Escherichia coli Nissle 1917 reduces the incidence of acute respiratory infections in late preterm newborns during the first month of life, with no adverse effects, highlighting its potential as a prophylactic intervention in this vulnerable population.